1. Michael L Reese  Is a corresponding author
  1. University of Texas Southwestern Medical Center, United States

Organisms that grow in close contact with one another often co-evolve. This is particularly evident in pathogens and their hosts, with each always needing to stay one small step ahead of the other in order to survive. This evolutionary competition has given rise to the systems of immune molecules that hosts use to recognize and neutralize invading pathogens, and also to the effector molecules that pathogens use to survive attack by the immune system. A prime example of this can be seen in the interactions between a class of enzymes called the immune-related GTPases (IRG proteins) and the pathogens that they recognize and destroy (Kim et al., 2012). It is known that IRG proteins work by assembling on the surface of the vacuoles within which the pathogens replicate, but the details of this mechanism are poorly understood.

Now, in eLife, Jonathan Howard of the University of Cologne and colleagues present striking evidence that the co-evolution of IRG proteins with Toxoplasma gondii—the parasite that causes toxoplasmosis—has been an important driving force in the functional evolution of the IRG system (Lilue et al., 2013). Howard and colleagues—including Jingtao Lilue as first author, Urs Muller and Tobias Steinfeldt—found that mice derived from wild mice were resistant to strains of the parasite that were lethal to laboratory mice. Remarkably, they demonstrated that this resistance was due to genetic variation in one particular form of IRG protein, named Irgb2-b1: they found that certain alleles of Irgb2-b1 appeared to inhibit the activity of the effector molecules secreted by the parasite, which themselves have evolved to inactivate the IRG system.

As it enters a new host cell, Toxoplasma secretes an active kinase called ROP18 and a diverse family of pseudokinases, called ROP5. The ROP5 pseudokinases appear to sequester the IRG proteins and then present them for phosphorylation by ROP18 (Fleckenstein et al., 2012). The process of phosphorylation inactivates the IRG proteins, which prevents them from assembling on the surface of the vacuole. This, in turn, allows the parasites to replicate (Figure 1; Steinfeldt et al., 2010; Fentress et al., 2010). There are considerable differences in the virulence (to mice) of the major strains of Toxoplasma, and genetic variations in ROP5 and ROP18 can explain almost all of these differences (Saeij et al., 2006; Taylor et al., 2006; Behnke et al., 2011; Reese et al., 2011). This highlights the importance of the IRG system in the control of Toxoplasma infection in mice, and the pressure that competition with this system has placed on the parasite.

Hosts vs parasites.

Toxoplasma parasites can kill laboratory mice (left) because they secrete effector molecules (ROP5 & ROP18) that prevent the effector IRG proteins (dark green) in the immune system of the mice from doing their job, which is to prevent the Toxoplasma parasites (grey) replicating themselves inside a vacuole. Lilue et al. show that in mice derived from wild mice (right), a particular isoform of an IRG protein (Irgb2-b1) binds to the ROP5 molecules, which means that the effector IRG proteins can assemble on the surface of the vacuole. This allows wild-derived mice to control an otherwise lethal infection in a way that, seemingly paradoxically, enables the survival of both the host and the parasite (which survives inside cysts in the brain and muscle tissue of the host).

As is typical of genes under strong selective pressure, the IRG genes differ both in copy number and in coding sequence in closely related species and even, as described by Lilue et al., among individuals within the same species. Previously the different forms of an IRG protein have been grouped into two distinct functional classes: effector IRG proteins that destroy the vacuoles inside which the pathogens replicate, and regulatory IRGs that are thought to inhibit premature activation of the system (Hunn et al., 2011). However, Irgb2-b1—the form of the protein identified by Lilue et al.—appears to belong to a third class of IRG proteins that recognize a particular pathogen effector rather than the pathogen itself. They found that Irgb2-b1 only attached itself to Toxoplasma vacuoles that were already coated with ROP5. Moreover, Irgb2-b1 loading appeared to block the activity of the ROP5 and ROP18 proteins. This left the effector IRG proteins free to assemble on the surface of the vacuole, thus leading to the destruction of the parasite (Figure 1). Strikingly, mice that carried the protective allele of Irgb2-b1 were able to survive acute infection with a highly virulent strain of the parasite, whereas infection by just one parasite of the same strain would kill a laboratory mouse.

Toxoplasma is also a survivor—as the acute infection ends, the parasite switches to a slow-growing form that becomes enclosed within cysts in the brain and muscle of the host, as was the case with the wild mice studied by Lilue et al. When a host is killed and eaten by a carnivore, the parasite switches back to a fast growing stage to infect its new host. Because strains of the parasite that secrete the virulent versions of both ROP5 and ROP18 are able to completely defeat the IRG system in laboratory mice, it was thought that these strains could not have co-evolved with mice, because the death of the host can be an evolutionary dead-end for a pathogen. The fact that Irgb2-b1 derived from wild mice represents a specific countermeasure to the parasite effectors provides a strong argument for co-evolution. The work of Lilue, Muller, Steinfeldt and Howard thus reminds us to look beyond lab-adapted organisms and examine biology in the wild to discover its full diversity.


Article and author information

Author details

  1. Michael L Reese

    Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, United States
    For correspondence
    Competing interests
    The author declares that no competing interests exist.

Publication history

  1. Version of Record published: October 29, 2013 (version 1)


© 2013, Reese

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.


  • 560
  • 50
  • 0

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Michael L Reese
Co-evolution: Immune to defeat
eLife 2:e01599.

Further reading

    1. Microbiology and Infectious Disease
    Michael D Sacco, Lauren R Hammond ... Yu Chen
    Research Article

    In the Firmicutes phylum, GpsB is a membrane associated protein that coordinates peptidoglycan synthesis with cell growth and division. Although GpsB has been studied in several bacteria, the structure, function, and interactome of Staphylococcus aureus GpsB is largely uncharacterized. To address this knowledge gap, we solved the crystal structure of the N-terminal domain of S. aureus GpsB, which adopts an atypical, asymmetric dimer, and demonstrates major conformational flexibility that can be mapped to a hinge region formed by a three-residue insertion exclusive to Staphylococci. When this three-residue insertion is excised, its thermal stability increases, and the mutant no longer produces a previously reported lethal phenotype when overexpressed in Bacillus subtilis. In S. aureus, we show that these hinge mutants are less functional and speculate that the conformational flexibility imparted by the hinge region may serve as a dynamic switch to finetune the function of the GpsB complex and/or to promote interaction with its various partners. Furthermore, we provide the first biochemical, biophysical, and crystallographic evidence that the N-terminal domain of GpsB binds not only PBP4, but also FtsZ, through a conserved recognition motif located on their C-termini, thus coupling peptidoglycan synthesis to cell division. Taken together, the unique structure of S. aureus GpsB and its direct interaction with FtsZ/PBP4 provide deeper insight into the central role of GpsB in S. aureus cell division.

    1. Microbiology and Infectious Disease
    Moagi Tube Shaku, Peter K Um ... Bavesh D Kana
    Research Article

    Mechanisms by which Mycobacterium tuberculosis (Mtb) evades pathogen recognition receptor activation during infection may offer insights for the development of improved tuberculosis (TB) vaccines. Whilst Mtb elicits NOD-2 activation through host recognition of its peptidoglycan-derived muramyl dipeptide (MDP), it masks the endogenous NOD-1 ligand through amidation of glutamate at the second position in peptidoglycan side-chains. As the current BCG vaccine is derived from pathogenic mycobacteria, a similar situation prevails. To alleviate this masking ability and to potentially improve efficacy of the BCG vaccine, we used CRISPRi to inhibit expression of the essential enzyme pair, MurT-GatD, implicated in amidation of peptidoglycan side-chains. We demonstrate that depletion of these enzymes results in reduced growth, cell wall defects, increased susceptibility to antibiotics, altered spatial localization of new peptidoglycan and increased NOD-1 expression in macrophages. In cell culture experiments, training of a human monocyte cell line with this recombinant BCG yielded improved control of Mtb growth. In the murine model of TB infection, we demonstrate that depletion of MurT-GatD in BCG, which is expected to unmask the D-glutamate diaminopimelate (iE-DAP) NOD-1 ligand, yields superior prevention of TB disease compared to the standard BCG vaccine. In vitro and in vivo experiments in this study demonstrate the feasibility of gene regulation platforms such as CRISPRi to alter antigen presentation in BCG in a bespoke manner that tunes immunity towards more effective protection against TB disease.